Clinical Observation Of Wenyang Method Intervent Ion On CD20 Monoclonal Antibody Plus Chemotherapy For Non-hodgkin’s Lymphoma Patients With Spleen-yang Deficiency Syndrome

Objective:For diseases such as malignant lymphoma that need to be treated with CD20 monoclonal antibody combined with chemotherapy,it can reduce the side effects after application of the drug,improve the patient’ s immunity,improve its quality of life,and provide therapeutic significance.Methods:Thirty-six hospitalized patients who were diagnosed with non-Hodgkin’ s lymphoma and diagnosed with spleen-yang deficiency syndrome in Qingdao Haici Medical Group and Affiliated Hospital of Qingdao University Medical College from January 2018 to June 2019 were selected.Those 46.75%patients of the survey were divided into two groups using a random number table,with 18 persons in each group.The observation group was given Fuzi Lizhong Decoction and R-CHOP chemotherapy.The control group received chemotherapy with R-CHOP alone.The efficacy was evaluated after 4 cycles.The KPS scores,Western medicine clinical symptom relief rate,TCM syndrome scores,blood routine and cardiac function classification,and the frequency of infections during treatment were compared between patients before and after treatment,and statistical software was used for data analysis.Results:After treatment,there was no significant difference in the clinical symptom relief rate of the two groups of Western medicine,indicating that chemotherapy still plays a dominant role in the treatment of NHL.The observation group had statistically significant differences in KPS scores,individual TCM syndrome scores,total syndrome scores,and overall efficacy.The observation group had significant effect.The WBC counts of both groups decreased after treatment.The observation group had a smaller degree of declining.There was no statistical significance.But it could still indicate efficacy in improving blood count with Wenyang method.The number of infections in the observation group was significantly less than that in the control group.There was no significant cardiac function change in the two groups.Conclusion:Fuzi Lizhong Decoction combined with R-CHOP chemotherapy treatment for patients with non-Hodgkin’ s lymphoma of spleen-yang deficiency can significantly improve the symptoms of spleen-yang deficiency,enhance the patient’ s constitution and reduce the incidence of infection,and improve the quality of life.It may have potential significance for reducing the bone marrow suppression caused by chemotherapeutic drugs and the cardiotoxicity caused by anthracycline chemotherapeutics.It can assist in the safe and effective development of anti-tumor therapy.It has advantages over R-CHOP alone,and is recommended for clinical use.